Business
Cantargia Announces Selection of Treatment Resistant Atopic Dermatitis as Second Target Indication for CAN10
LUND, SE / ACCESS Newswire / April 29, 2025 / Cantargia (STO:CANTA) Atopic dermatitis (AD) is a very common, heterogeneous and debilitating disease with a need for new treatment options CAN10 targets several pathways relevant for AD but distinct from ...
About this update from Cantargia Ab
[{"type":"text","content":"LUND, SE / ACCESS Newswire / April 29, 2025 / Cantargia (STO:CANTA)","length":67,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Atopic dermatitis (AD) is a very common, heterogeneous and debilitating disease with a need for new treatment options","length":117,"tagName":"p"}]},{"val":[{"type":"text","content":"CAN10 targets several pathways relevant for AD but distinct from current treatments' mode of action","length":103,"tagName":"p"}]},{"val":[{"type":"text","content":"A pilot phase 2 study will test CAN10 in a subgroup of patients with moderate to severe AD not responding to current first line biologic treatment","length":146,"tagName":"p"}]},{"val":[{"type":"text","content":"Clinical results expected within 12 months of study initiation","length":62,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":428,"olType":false},{"type":"text","content":"Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced the selection of a subgroup of atopic dermatitis (AD) patients, not responding to first line dupilumab treatment, as its second target indication for CAN10. Cantargia has received strong support from key opinion leaders in developing CAN10 for AD and will test it in a subset of patients where targeting of other pathways has failed. This indication will complement CAN10's lead indication, hidradenitis suppurativa (HS) and align with the project's initial focus on inflammatory dermatological diseases. The clinical study will be a pilot Phase 2 study that can start in parallel with the HS trial with data expected within 12 months of study initiation.","length":735,"tagName":"p"},{"type":"text","content":""As Atopic Dermatitis is an immunologically and phenotypically heterogenous disease, which can involve both the innate and adaptive parts of the immune system, targeting the broad IL-1 family of cytokines by blocking IL1RAP appears promising, and could be very effective, even in the around 10% of people with moderate to severe AD who are complete non-responders to IL-4 and IL-13 blockage.", said Prof. Thomas Bieber, MD, PhD, MDRA, Professor of Dermatology and Allergy, Davos and Zurich, Switzerland","length":512,"tagName":"p"},{"type":"text","content":"CAN10 is an antibody against IL1RAP designed to potently inhibit the activity of the pro-inflammatory and dis...